Docoh
Loading...

RGEN Repligen

News

Pro users get this 30m faster
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
14 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Exane BNP Paribas Initiates Coverage On Repligen with Outperform Rating, Announces Price Target of $330
14 Oct 21
News, Price Target, Initiation, Analyst Ratings
Exane BNP Paribas initiates coverage on Repligen (NASDAQ:RGEN) with a Outperform rating and announces Price Target of $330.
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
30 Sep 21
Biotech, Earnings, M&A, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29)
Craig-Hallum Maintains Buy on Repligen, Raises Price Target to $368
27 Sep 21
News, Price Target, Analyst Ratings
Craig-Hallum analyst Matt Hewitt maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $258 to $368.
The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep 21
Biotech, News, Penny Stocks, Health Care, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22)
The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep 21
Biotech, M&A, News, Penny Stocks, Offerings, Small Cap, FDA, Legal, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)
10 Biggest Price Target Changes For Friday
17 Sep 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
UBS cut FedEx Corporation (NYSE: FDX) price target from $397 to $380. FedEx shares fell 0.2% to $258.00 in pre-market trading.
The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16)
Keybanc Maintains Overweight on Repligen, Raises Price Target to $335
17 Sep 21
News, Price Target, Analyst Ratings
Keybanc analyst Paul Knight maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the price target from $255 to $335.
Repligen Reinforces Proteins Business With $150M Avitide Acquisition Deal
16 Sep 21
Biotech, M&A, News, Health Care, General
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15)
Repligen To Acquire Avitide For $150M
16 Sep 21
M&A
Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 million, comprised of $75 million in cash plus $75 million in Repligen common stock in addit
Chief Executive Officer Of Repligen Trades $8.18 Million In Company Stock
14 Sep 21
News, Insider Trades, Trading Ideas
Anthony Hunt, Chief Executive Officer at Repligen (NASDAQ:RGEN), made a large buy and sell of company shares on September 9, according to a new SEC filing.
Repligen And Navigo GmbH Announce Launch Of Industry-First Protein A Ligand for Purification Of pH Sensitive Antibodies
9 Sep 21
News
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation
The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod
8 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 7)
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
3 Sep 21
Biotech, News, Penny Stocks, Small Cap, Legal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2)
Repligen Senior VP Makes $1.13 Million Sell
2 Sep 21
News, Insider Trades, Trading Ideas
Ralf Kuriyel, Senior VP and RD at Repligen (NASDAQ:RGEN), made a large insider sell on August 30, according to a new SEC filing.
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
2 Sep 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1)
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
1 Sep 21
Biotech, Earnings, News, Penny Stocks, Offerings, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31)

Press releases

Pro users get this 30m faster
Repligen to Report Third Quarter 2021 Financial Results
14 Oct 21
News, Press Releases
Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its
Repligen Announces Agreement to Acquire Avitide Inc.
16 Sep 21
M&A, News, Press Releases
Proposed acquisition strengthens Repligen's Proteins business Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH Strategically moves Repligen into
Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies
9 Sep 21
Health Care, Press Releases, General
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH ("Navigo"), today announced they
Thinking about trading options or stock in Sonos, MicroStrategy, eBay, Pfizer, or Repligen Corp?
16 Aug 21
Opinion, Press Releases
NEW YORK, Aug. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONO, MSTR, EBAY, PFE, and RGEN.
Repligen Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
27 Jul 21
Earnings, Press Releases
Reported revenue was $163.0 million for the quarter, representing year-over-year growth of 86% and organic growth of 69%Revenue guidance raised to $625-$645 million for full year 2021Acquisition of hollow fiber innovator